Evogene Ltd. (NASDAQ:EVGN) Short Interest Down 81.9% in July

Posted by Francis Steltz on Aug 12th, 2026

Evogene Ltd. (NASDAQ:EVGN – Get Free Report) saw a significant decline in short interest during the month of July. As of July 31st, there was short interest totaling 45,127 shares, a decline of 81.9% from the July 15th total of 248,770 shares. Based on an average daily trading volume, of 210,507 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.6% of the shares of the company are short sold.

Institutional Investors Weigh In On Evogene

Hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new position in shares of Evogene during the 4th quarter worth approximately $25,000. Jane Street Group LLC grew its holdings in Evogene by 58.0% during the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 12,387 shares during the period. Finally, Citadel Advisors LLC grew its holdings in Evogene by 169.4% during the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 36,206 shares during the period. Institutional investors and hedge funds own 10.40% of the company’s stock.

Evogene Trading Up 10.8%

Shares of EVGN stock opened at $0.70 on Wednesday. The company has a market capitalization of $6.11 million, a P/E ratio of -0.50 and a beta of 1.40. The business’s 50 day moving average is $0.53 and its two-hundred day moving average is $0.73. Evogene has a twelve month low of $0.37 and a twelve month high of $1.50.

Evogene (NASDAQ:EVGN – Get Free Report) last issued its quarterly earnings results on Saturday, May 16th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.33). The company had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.35 million. Evogene had a negative return on equity of 158.82% and a negative net margin of 638.12%.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Evogene in a research report on Wednesday, July 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Get Our Latest Research Report on EVGN

Evogene Company Profile

(Get Free Report)

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.